The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression.
The oncofetal Thomsen-Friedenreich carbohydrate antigen (Galbeta1-3GalNAcalpha1-Ser/Thr TF or T antigen) is a pan-carcinoma antigen highly expressed by about 90% of all human carcinomas. Its broad expression and high specificity in cancer have attracted many investigations into its potential use in cancer diagnosis and immunotherapy. Over the past few years increasing evidence suggests that the increased TF occurrence in cancer cells may be functionally important in cancer progression by allowing increased interaction/communication of the cells with endogenous carbohydrate-binding proteins (lectins), particularly the members of the galactoside-binding galectin family. This review focuses on the recent progress in understanding of the regulation and functional significance of increased TF occurrence in cancer progression and metastasis.
Yu
Lu-Gang
LG
The Henry Wellcome Laboratory of Molecular and Cellular Gastroenterology, School of Clinical Science, University of Liverpool, Liverpool, L69 3BX, UK. lgyu@liverpool.ac.uk
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000378:metabolism*; D002448:Cell Adhesion; D049109:Cell Proliferation; D018450:Disease Progression; D004727:Endothelium / Q000378:metabolism; D006801:Humans; D018396:Mucin-1 / Q000378:metabolism; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology; D009389:Neovascularization, Pathologic
D015295:Antigens, Tumor-Associated, Carbohydrate; C060192:MUC1 protein, human; D018396:Mucin-1; C016467:Thomsen-Friedenreich antigen